Antibody diversity includes conventional, HCAbs, and VHHs. Biointron explores these formats and their roles in therapy, diagnostics, and antibody research.
VHH antibodies trace back to camelids. Biointron explains their discovery, unique properties, and how they advance modern diagnostics and therapeutics.
ADCs are reshaping biopharma. Biointron explores how antibody-drug conjugates combine precision targeting with potent payloads to transform therapies.
Biointron delivers results in just 2 weeks. Our ISO-certified platforms accelerate antibody services, ensuring high-quality, fast, and reliable outcomes.
Antibody-mediated (humoral) immunity is central to defense. Biointron highlights mechanisms and their importance in health, research, and therapeutics.
The immune system defends through innate and adaptive arms. Biointron explains their roles in disease protection and therapeutic antibody development.
Stability and efficacy define therapeutic antibodies. Biointron reviews methods to maintain monoclonal antibody performance throughout development and use.
Monoclonal antibody formulation ensures stability and efficacy. Biointron outlines strategies to design formulations that preserve quality and therapeutic impact.
Advanced techniques optimize antibody drug development. Biointron shows how CHO cells and process innovations improve yields, stability, and therapeutic outcomes.
Single B cell screening is evolving fast. Biointron highlights emergent technologies that boost efficiency, speed, and precision in antibody discovery.
Hybridoma technologies laid the foundation for antibody discovery. Biointron explains conventional methods and their lasting value in monoclonal development.
Antibody-drug conjugates unite targeting precision with potent drugs. Biointron reviews their innovation and transformative role in cancer treatment.
You can also contact us on the Scientist and Science Exchange marketplaces.